Analystreport

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) had its price target lowered by analysts at Piper Sandler from $208.00 to $204.00. They now have an "overweight" ratin

Madrigal Pharmaceuticals, Inc.  (MDGL) 
Last madrigal pharmaceuticals, inc. earnings: 2/26 06:50 am Check Earnings Report
US:NASDAQ Investor Relations: madrigalpharma.com